Dr. Toni K. Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at the Dana-Farber Cancer Institute (DFCI)/Brigham and Women’s Hospital and Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School. He is the Leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center and past President of the Medical Staff at Dana-Farber (2016-2018). He is the recipient of the George Canellos Award for Excellence in Clinical Investigation and Patient Care from DFCI and the Eugene P. Schonfeld Award from the KCA. He serves on the National Comprehensive Cancer Network (NCCN) Kidney Cancer Panel, the National Cancer Institute (NCI) GU Steering Committee and is past Chairman (2015-2018) of the Medical and Scientific Steering Committee of the Kidney Cancer Association (KCA). In addition, he is an Aresty Scholar from the Wharton School of Business at the University of Pennsylvania.
Dr. Choueiri is interested in developing novel experimental therapies and biomarkers in GU malignancies, including renal cell carcinoma (RCC). Dr. Choueiri and colleagues have made several seminal observations that have defined the treatment of RCC with the approval of several treatments such as Cabozantinib, Cabozantinib+Nivolumab, Pazopanib, and Avelumab+Axitinib in a series of New England Journal of Medicine (NEJM) articles for which Dr. Choueiri was the first or senior author. His research also focuses on the epidemiology, diagnosis, and treatment outcomes of GU cancers, having co-established the IMDC criteria for RCC risk stratification. His biomarker work has shed light on complex immunogenomics mechanisms contributing to response and resistance to targeted therapy and immunotherapy.
He has been funded by the NCI, the Department of Defense (DOD), the American Society of Clinical Oncology (ASCO), the Harvard Kidney Cancer SPORE, and Industry partners. His work has been published in journals such as the NEJM, Nature, Nature Medicine, Science, Cancer Cell, Journal of American Medical Association, Journal of Clinical Oncology, Lancet Oncology, Clinical Cancer Research, and many others. He lectures frequently throughout the United States and around the world. He has over 550 PubMed-listed publications and is the lead investigator of multiple national and international phase I-III trials in GU cancers.